Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2018

Open Access 01-12-2018 | Review

Quality of reporting of outcomes in phase III studies of pulmonary tuberculosis: a systematic review

Authors: Laura Jayne Bonnett, Gie Ken-Dror, Geraint Rhys Davies

Published in: Trials | Issue 1/2018

Login to get access

Abstract

Background

Despite more than 60 years of clinical trials, tuberculosis (TB) still causes a high global burden of mortality and morbidity. Treatment currently requires multiple drugs in combination, taken over a prolonged period. New drugs are needed to shorten treatment duration, prevent resistance and reduce adverse events. However, to improve on current methodology in drug development, a more complete understanding of the existing clinical evidence base is required.

Methods

A systematic review was undertaken to summarise outcomes reported in phase III trials of patients with newly diagnosed pulmonary TB. A systematic search of databases (PubMed, MEDLINE, EMBASE, CENTRAL and LILACs) was conducted on 30 November 2017 to retrieve relevant peer-reviewed articles. Reference lists of included studies were also searched. This systematic review considered all reported outcomes.

Results

Of 248 included studies, 229 considered “on-treatment” outcomes whilst 148 reported “off-treatment” outcomes. There was wide variation and ambiguity in the definition of reported outcomes, including their relationship to treatment and in the time points evaluated. Additional challenges were observed regarding the analysis approach taken (per protocol versus intention to treat) and the varying durations of “intensive” and “continuation” phases of treatment. Bacteriological outcomes were most frequently reported but radiological and clinical data were often included as an implicit or explicit component of the overall definition of outcome.

Conclusions

Terminology used to define long-term outcomes in phase III trials is inconsistent, reflecting evolving differences in protocols and practices. For successful future cumulative meta-analysis, the findings of this review suggest that greater availability of individual patient data and the development of a core outcome set would be desirable. In the meantime, we propose a simple and logical approach which should facilitate combination of key evidence and inform improvements in the methodology of TB drug development and clinical trials.
Appendix
Available only for authorised users
Literature
1.
2.
3.
4.
Nunn AJ, Phillips PP, Gillespie SH. Design issues in pivotal drug trials for drug sensitive tuberculosis (TB). Tuberculosis. 2008;88:S85–92.CrossRefPubMed
5.
Van Niekerk C, Ginsberg A. Assessment of global capacity to conduct tuberculosis drug development trials: do we have what it takes? Int J Tuberc Lung Dis. 2009;13(11):1367–72.PubMed
6.
Lienhardt C, Raviglione M, Spigelman M, Hafner R, Jaramillo E, Hoelscher M, Zumla A, Gheuens J. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis. 2012;205:S241–9.CrossRefPubMed
7.
Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials: The CONSORT statement. JAMA. 1996;276:637–9.CrossRefPubMed
8.
Hong Kong Chest Service, Tuberculosis Research Centre, Madras, India, and British Medical Research Council. Sputum-smear-negative pulmonary tuberculosis: controlled trial of 3-month and 2-month regimens of chemotherapy. Lancet. 1979;1(8131):1361–3.
9.
Hong Kong Chest Service, Tuberculosis Research Centre, Madras, India, and British Medical Research Council. A controlled trial of a 2-month, 3-month, and 12-month regimens of chemotherapy for sputum smear-negative pulmonary tuberculosis: the results at 30 months. Am Rev Respir Dis. 1981;124(2):138–42.
10.
Hong Kong Chest Service, Tuberculosis Research Centre, Madras, India, and British Medical Research Council. A controlled trial of 2-month, 3-month, and 12-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 60 months. Am Rev Respir Dis. 1984;130(1):23–8.
11.
Dawson J, Devadatta S, Fox W, Radhakrishna S, Ramakrishnan C, Somasundaram P, Stott H, Tripathy S, Velu S. A 5-year study of patients with pulmonary tuberculosis in a concurrent comparison of home and sanatorium treatment for one year with isoniazid plus PAS. Bull World Health Organ. 1966;34(4):533–51.PubMedPubMedCentral
12.
Devadatta S, Andrews R, Angel J, Bhatia A, Fox W, Janardhanam B, Radhakrishna S, Ramakrishnan C, Subbaiah T, Velu S. Progress in the second and third years of patients with quiescent pulmonary tuberculosis after a year of chemotherapy at home or in sanatorium, and influence of further chemotherapy on the relapse rate. Bull World Health Organ. 1961;24:149–75.PubMedPubMedCentral
13.
Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, Hatherill M, Geldenhuys H, McIlleron HM, Zvada SP. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014;371:1599–608.CrossRefPubMedPubMedCentral
14.
Engbaek H, Heckscher T, Højgaard C, Larsen S, Rasmussen K, Vergmann B. Tuberculosis treated with rifampicin, ethambutol and isoniazid: Danish tuberculosis trial 1972-1974. Eur J Respir Dis. 1982;63(2):84–93.PubMed
15.
Santha T, Rehman F, Mitchison D, Sarma G, Reetha A, Prabhaker R. Split-drug regimens for the treatment of patients with sputum smear-positive pulmonary tuberculosis--a unique approach. Trop Med Int Health. 2004;9:551–8.CrossRefPubMed
16.
Balasubramanian RSS, Vijayan VK, Ramachandran R, Jawahar MS, Paramasivan CN, Selvakumar N, Somasundaram PR. Five year results of a 3-month and two 5-month regimens for the treatment of sputum-positive pulmonary tuberculosis in south India. Tubercle. 1990;71:253–8.CrossRefPubMed
17.
Paunescu E. Preliminary results of a short-course antituberculosis regimen including Sinerdol-EH and applied under operational conditions. Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol. 1985;34(2):149–55.PubMed
18.
East African and British Medical Research Councils. Controlled clinical trial of short-course (6 month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet. 299:1079–85.
19.
East African and British Medical Research Councils. Isoniazid with thiacetazone (thioacetazone) in the treatment of pulmonary tuberculosis in East Africa. Third Report of Fifth Investigation. A co-operative study in East Africian hospitals, clinics and laboratories with the collaboration of the East African and British Medical Research Councils. Tubercle. 1973;54:169–79.
20.
Hong Kong Chest Service/British Medical Research Council. Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis. 1987;136:1339–42.CrossRef
21.
Cooperative Study Unit of Chemotherapy of Tuberculosis of National Sanatoria in Japan (CSUCTNS). A controlled trial of 6-month and 12-month regimens after negative conversion of sputum in the original treatment of pulmonary tuberculosis. Report of the 21st series of controlled trials of chemotherapy. Kekkaku 1984;59(2):81–89.
22.
Van Deun A, Aung KJM, Hamid Salim MA, Ali MA, Naha MS, Das PK, Hossain MA, Declercq E. Extension of the intensive phase reduces unfavourable outcomes with the 8-month thioacetazone regimen. Int J Tuberc Lung Dis. 2006;10(11):1255–61.PubMed
23.
Priĭmak AASM, VIa S, Tarasova EF, Goncharov AM, Glazkov PV, Makeenkova LI, Ladniuk VM. Preliminary results of a study on shortening periods of treatment and temporary disability of patients with tuberculosis of the respiratory organs. Problmy Tuberkuleza. 1989;10:15–8.
24.
Velu S, Andrews RH, Angel JH, Devadatta S, Fox W, Gangadharam PRJ, Narayana ASL, Ramakrishnan CV, Selkon JB, Somasundaram PR. Progress in the second year of patients with quiescent pulmonary tuberculosis after a year of domiciliary chemotherapy, and influence of further chemotherapy on the relapse rate. Bull World Health Organ. 1961;25(3):409–29.PubMedPubMedCentral
25.
Muschenheim C, McDermott W, McCune R, Deuschle K, Ormond L, Tompsett R. Pyrazinamide-isoniazid in tuberculosis. II. Results in 58 patients with pulmonary lesions one year after the start of therapy. Am Rev Tuberc. 1954;70(4):743–7.PubMed
26.
Gravendeel JM, Asapa AS, Becx-Bleumink M, Vrakking HA. Preliminary results of an operational field study to compare side-effects, complaints and treatment results of a single-drug short-course regimen with a four-drug fixed-dose combination (4FDC) regimen in South Sulawesi, Republic of Indonesia. Tuberculosis. 2003;83:183–6.CrossRefPubMed
27.
Baba H, Shinkai A, Azuma Y. Controlled clinical trial of three 6 month regimens of chemotherapy for pulmonary tuberculosis (preliminary report). Kekkaku (Tuberculosis). 1978;53(5):287–94.PubMed
28.
African E. Isoniazid with thiacetazone (thioacetazone) in the treatment of pulmonary tuberculosis in East Africa-Third Investigation: the effect of an initial streptomycin supplement. A co-operative study in East African Hospitals and Laboratories. Tubercle. 1966;47:1–32.CrossRef
29.
Jacob MC, Joseph MS, Venkataraman MP, Kailasam MS, Prema MK, Raghunathan MR, Narayana MA. A controlled comparison of a twice-weekly and three once-weekly regimens in. Bull Org Mond Sant. 1970;43:143–206.
30.
Doster B, Murray FJ, Newman R, Woolpert SF. Ethambutol in the initial treatment of pulmonary tuberculosis. U.S. Public Health Service tuberculosis therapy trials. Am Rev Respir Dis. 1973;107(2):177–90.PubMed
31.
Snider Jr D, Long M, Cross F, Farer L. Six-months isoniazid-rifampin therapy for pulmonary tuberculosis. Report of a United States Public Health Service Cooperative Trial. Am Rev Respir Dis. 1984;129(4):573–9.
32.
Tam C, Chan S, Lam C, Leung C, Kam K, Morris J, Mitchison D. Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis: initial report. Am J Respir Crit Care Med. 1998;157:1726–33.CrossRefPubMed
33.
Lienhardt C, Cook SV, Burgos M, et al. Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial. JAMA. 2011;305:1415–23.CrossRefPubMed
34.
Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, Pappas F, Phillips PPJ, Nunn AJ. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014;371:1577–87.CrossRefPubMedPubMedCentral
35.
36.
37.
Metadata
Title
Quality of reporting of outcomes in phase III studies of pulmonary tuberculosis: a systematic review
Authors
Laura Jayne Bonnett
Gie Ken-Dror
Geraint Rhys Davies
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Trials / Issue 1/2018
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-018-2522-x

Other articles of this Issue 1/2018

Trials 1/2018 Go to the issue

Study protocol

Reduced fetal movement intervention Trial-2 (ReMIT-2): protocol for a pilot randomised controlled trial of standard care informed by the result of a placental growth factor (PlGF) blood test versus standard care alone in women presenting with reduced fetal movement at or after 36+ 0 weeks gestation

Study protocol

Effect of preconceptional orlistat treatment on in-vitro fertilization outcome in overweight/obese women: study protocol for a randomized controlled trial

Research

Patient understanding and acceptability of an early lung cancer diagnosis trial: a qualitative study

Study protocol

Smartphone-based ecological momentary assessment and intervention in a coping-focused intervention for hearing voices (SAVVy): study protocol for a pilot randomised controlled trial

Correction

Correction to: Effectiveness and acceptance of a web-based depression intervention during waiting time for outpatient psychotherapy: study protocol for a randomized controlled trial

Study protocol

Efficacy and safety of Ding-Kun-Dan for female infertility patients with predicted poor ovarian response undergoing in vitro fertilization/intracytoplasmic sperm injection: study protocol for a randomized controlled trial